Regulus Therapeutics Inc (RGLS)

1.15
0.05 4.17
NASDAQ : Health Care
Prev Close 1.20
Open 1.20
Day Low/High 1.05 / 1.20
52 Wk Low/High 2.44 / 10.60
Volume 2.02M
Avg Volume 804.00K
Exchange NASDAQ
Shares Outstanding 52.92M
Market Cap 63.51M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Regulus Therapeutics Inc.

Regulus Announces Continuation Of RG-101 Clinical Hold

Regulus Announces Continuation Of RG-101 Clinical Hold

FDA requests longer-term follow-up data from ongoing studies

Regulus To Release Third Quarter Financial Results On November 1, 2016

Regulus To Release Third Quarter Financial Results On November 1, 2016

Conference Call and Webcast to Follow

Regulus Provides Update On Clinical Hold Of RG-101

Regulus Provides Update On Clinical Hold Of RG-101

On Track to Deliver Follow-up Results from On-going RG-101 Studies

Regulus To Release Second Quarter Financial Results On August 2, 2016

Regulus To Release Second Quarter Financial Results On August 2, 2016

Conference Call and Webcast to Follow

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Regulus Therapeutics Inc. - RGLS

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Regulus Therapeutics Inc. - RGLS

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Regulus Therapeutics Inc.

Regulus Reports Clinical Hold Of RG-101

Regulus Reports Clinical Hold Of RG-101

Timelines of On-going Studies are not Expected to be Impacted

Interesting RGLS Put And Call Options For February 2017

Interesting RGLS Put And Call Options For February 2017

Investors in Regulus Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.